-
公开(公告)号：US10898443B2
公开(公告)日：2021-01-26
申请号：US16108465
申请日：2018-08-22
Inventor： Arturo J. Vegas , Joshua C. Doloff , Omid Veiseh , Minglin Ma , Robert S. Langer , Daniel G. Anderson
IPC: A61K35/39 , A61K9/00 , A61K9/50 , A61L29/08 , A61L31/10 , C08B37/00 , C12N5/00 , C12N5/071 , A61L33/08
Abstract: Covalently modified alginate polymers, possessing enhanced biocompatibility and tailored physiochemical properties, as well as methods of making and use thereof, are disclosed herein. The covalently modified alginates are useful as a matrix for coating of any material where reduced fibrosis is desired, such as encapsulated cells for transplantation and medical devices implanted or used in the body.
-
公开(公告)号：US20200155660A1
公开(公告)日：2020-05-21
申请号：US16692624
申请日：2019-11-22
Inventor： Omar F. Khan , Jasdave S. Chahal , Daniel G. Anderson , Hidde Ploegh , Robert S. Langer , Tyler E. Jacks , David A. Canner
IPC: A61K39/00 , A61K31/713 , A61K39/12 , C12N15/87 , A61K48/00 , A61K39/002 , A61K9/00 , C12N15/88 , A61K39/145 , A61K9/51
Abstract: Compositions and methods for modified dendrimer nanoparticle (“MDNP”) delivery of therapeutic, prophylactic and/or diagnostic agent such as large repRNA molecules to the cells of a subject have been developed. MDNPs efficiently drive proliferation of antigen-specific T cells against intracellular antigen, and potentiate antigen-specific antibody responses. MDNPs can be multiplexed to deliver two or more different repRNAs to modify expression kinetics of encoded antigens and to simultaneous deliver repRNAs and mRNAs including the same UTR elements that promote expression of encoded antigens.
-
公开(公告)号：US10548959B2
公开(公告)日：2020-02-04
申请号：US15274954
申请日：2016-09-23
Inventor： Omar F. Khan , Jasdave S. Chahal , Daniel G. Anderson , Hidde Ploegh , Robert S. Langer , Tyler E. Jacks , David A. Canner
IPC: A61K9/00 , A61K39/00 , A61K31/713
Abstract: Compositions and methods for modified dendrimer nanoparticle (“MDNP”) delivery of therapeutic, prophylactic and/or diagnostic agent such as large repRNA molecules to the cells of a subject have been developed. MDNPs efficiently drive proliferation of antigen-specific T cells against intracellular antigen, and potentiate antigen-specific antibody responses. MDNPs can be multiplexed to deliver two or more different repRNAs to modify expression kinetics of encoded antigens and to simultaneous deliver repRNAs and mRNAs including the same UTR elements that promote expression of encoded antigens.
-
公开(公告)号：US10292936B2
公开(公告)日：2019-05-21
申请号：US15588481
申请日：2017-05-05
Inventor： Arturo J. Vegas , Minglin Ma , Kaitlin M Bratlie , Daniel G. Anderson , Robert S. Langer
Abstract: Covalently modified alginate polymers, possessing enhanced biocompatibility and tailored physiochemical properties, as well as methods of making and use thereof, are disclosed herein. The covalently modified alginates are useful as a matrix for the encapsulation and transplantation of cells. Also disclosed are high throughput methods for the characterizing the biocompatibility and physiochemical properties of modified alginate polymers.
-
公开(公告)号：US10278922B2
公开(公告)日：2019-05-07
申请号：US15831570
申请日：2017-12-05
Inventor： Daniel G. Anderson , Robert S. Langer , Tram T. Dang
IPC: A61K9/16 , A61K9/00 , A61K31/573 , A61K45/06 , A61K35/39 , G01N33/50 , A61L27/38 , A61L27/48 , A61L27/52 , A61L27/54 , C12N5/071
Abstract: A composition containing biocompatible hydrogel encapsulating mammalian cells and anti-inflammatory drugs is disclosed. The encapsulated cells have reduced fibrotic overgrowth after implantation in a subject. The compositions contain a biocompatible hydrogel having encapsulated therein mammalian cells and anti-inflammatory drugs or polymeric particles loaded with anti-inflammatory drugs. The anti-inflammatory drugs are released from the composition after transplantation in an amount effective to inhibit fibrosis of the composition for at least ten days. Methods for identifying and selecting suitable anti-inflammatory drug-loaded particles to prevent fibrosis of encapsulated cells are also described. Methods of treating a disease in a subject are also disclosed that involve administering a therapeutically effective amount of the disclosed encapsulated cells to the subject.
-
Patent Agency Ranking
公开(公告)号：US20180187186A1
公开(公告)日：2018-07-05
申请号：US15741211
申请日：2016-06-29
Applicant: Massachusetts Institute of Technology
Inventor： Hao Yin , Daniel G. Anderson , Robert Samuel Langer
CPC classification number: C12N15/11 , A61K48/005 , C07H21/02 , C07H21/04 , C12N9/22 , C12N9/96 , C12N15/907 , C12N2310/20 , C12N2310/322 , C12N2800/80
Abstract: The disclosure relates to compositions comprising and methods for chemical modification of single guide RNA (sgRNA), tracrRNA and/or crRNA used individually or in combination with one another or Cas system components. Compositions comprising modified ribonucleic acids have been designed with chemical modification for even higher efficiency as unmodified native strand of sgRNA. Administration of modified ribonucleic acids will allow decreased immune response when administered to a subject, increased stability, increased editing efficiency and facilitated in vivo delivery of sgRNA via various delivery platforms. The disclosure also relates to methods of decreasing off-target effect of CRISPR and a CRISPR complex.
-
公开(公告)号：US09970002B2
公开(公告)日：2018-05-15
申请号：US14652038
申请日：2013-12-12
Inventor： Daniel G. Anderson , Rosemary Lynn Kanasty , Arturo Jose Vegas , Robert S. Langer
IPC: C12N15/113 , C12N15/11
CPC classification number: C12N15/113 , C12N15/111 , C12N2310/14 , C12N2310/351 , C12N2310/3515 , C12N2310/3517 , C12N2320/32
Abstract: Provided are derivatized therapeutic, prophylactic, or diagnostic agents, such as nucleic acids, that can be effectively delivered to cells and tissues. Also provided are methods of affecting a biological process by administering a therapeutic, prophylactic, or diagnostic agent, such as functional nucleic acid, to a cell or a subject, where the therapeutic, prophylactic, or diagnostic agent, such as functional nucleic acid, is derivatized therapeutic, prophylactic, or diagnostic agent, such as nucleic acid.
-
公开(公告)号：US20170117312A1
公开(公告)日：2017-04-27
申请号：US15294914
申请日：2016-10-17
Applicant: Massachusetts Institute of Technology
Inventor： Virginia Spanoudaki , Daniel G. Anderson , Robert S. Langer
IPC: H01L27/146 , H01L29/06
CPC classification number: H01L27/14616 , G01T1/2018 , G01T1/241 , G01T1/247 , H01L27/14605 , H01L27/14636 , H01L29/0669
Abstract: A sensor comprises a substrate; an array of nanowire field effect transistors (NWFETs) formed in said substrate, each of the NWFETs having source, drain and gate terminals; a nanowire coupled between the source terminal and the drain terminal of each NWFET; and a layer of radiation sensitive material disposed over said NWFETs and said nanowires with each of the source, drain and gate terminals configured to be coupled to respective ones of first, second or third reference potentials, wherein each NWFET is configured such that the conductivity between the source and drain changes in response to radiation absorbed in the layer of radiation sensitive material such that the sensor generates an output signal in response to radiation absorbed by the radiation sensitive material.
-
公开(公告)号：US09339529B2
公开(公告)日：2016-05-17
申请号：US14379481
申请日：2013-02-19
Inventor： Daniel G. Anderson , Zhen Gu , Robert S. Langer
CPC classification number: A61K38/28 , A61K9/0019 , A61K9/5026 , A61K9/5031 , A61K9/5036 , A61K9/5138 , A61K9/5161 , A61K38/44 , A61K38/443 , C12Y101/03004 , C12Y111/01006 , A61K2300/00
Abstract: Injectable insulin loaded microgels that are capable of modifying the amount of insulin released based on the patient's tissue glucose levels, methods for making and using these compositions have been developed. The microgels contain insulin, glucose oxidase entrapped in or bound to the microgels, and an agent that reduces hydrogen peroxide, entrapped in or bound to the microgels, wherein the polymeric microgel expands when pH decreases from physiological pH and shrinks when pH increases towards physiological pH, thereby releasing insulin at a rate corresponding to the glucose concentration. In one embodiment, the glucose oxidase and/or the agent reducing hydrogen peroxide are encapsulated in nanogels, then encapsulated within the microgel.
Abstract translation: 已经开发了能够改变基于患者组织葡萄糖水平释放的胰岛素量的可注射胰岛素负载微凝胶，制备和使用这些组合物的方法。 微凝胶含有胰岛素，包裹在微凝胶中或与微凝胶结合的葡萄糖氧化酶，以及减少过氧化氢，夹带或结合到微凝胶上的试剂，其中当pH从生理pH降低时，聚合物微凝胶膨胀，并且当pH向生理pH增加时收缩 从而以对应于葡萄糖浓度的速度释放胰岛素。 在一个实施方案中，葡萄糖氧化酶和/或还原过氧化氢的试剂被包封在纳米凝胶中，然后封装在微凝胶内。
-
公开(公告)号：US20150320837A1
公开(公告)日：2015-11-12
申请号：US14652011
申请日：2013-12-12
Applicant: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
Inventor： Daniel G. Anderson , Hung-Chieh Chou , Matthew J. Webber , Benjamin C. Tang , Yair Levi , Yunlong Zhang , Rosemary Lynn Kanasty , Arturo Jose Vegas , Robert A. Langer
CPC classification number: A61K38/28 , A61K47/54 , A61K47/542 , A61K47/543 , A61K47/549 , A61K47/554 , G01N33/66 , G01N33/74 , G01N2333/62
Abstract: Compounds, compositions, and methods for “smart” delivery of a therapeutic, prophylactic or diagnostic agent, such as glucose-mediated delivery of insulin through glucose-sensing insulin derivatives, are provided. The insulin derivatives bind serum albumin or agglomerate in vivo. The insulin derivatives effectively dissociate to release insulin in a hyperglycemic condition, where the complexation of glucose to a glucose-sensing element alters properties of the insulin derivative leading to the dissociation. The compounds, compositions, and methods provide a delivery strategy for both self-regulated and long-term diabetes management.
Abstract translation: 提供了通过葡萄糖感测胰岛素衍生物“治疗性”，“预防性”或“诊断”（例如葡萄糖介导的胰岛素递送）的“智能”递送的化合物，组合物和方法。 胰岛素衍生物在体内结合血清白蛋白或附聚物。 胰岛素衍生物有效解离以在高血糖状态释放胰岛素，其中葡萄糖与葡萄糖感测元件的络合改变导致胰岛素衍生物的分解导致解离。 化合物，组合物和方法提供了自我调节和长期糖尿病管理的递送策略。
-
-
-
-
-
-
-
-
-
Search Results
104
records
(took 0.039 seconds)
